{"id":1315670,"date":"2026-11-11T12:04:39","date_gmt":"2026-11-11T06:34:39","guid":{"rendered":"https:\/\/trak.in\/stories\/?p=1315670"},"modified":"2026-11-11T12:04:54","modified_gmt":"2026-11-11T06:34:54","slug":"popular-glp-1-weight-loss-drugs-can-cause-permanent-blindness-us-fda","status":"publish","type":"post","link":"https:\/\/trak.in\/stories\/popular-glp-1-weight-loss-drugs-can-cause-permanent-blindness-us-fda\/","title":{"rendered":"Popular GLP-1 Weight Loss Drugs Can Cause Permanent Blindness – US FDA"},"content":{"rendered":"\n

The US Food and Drug Administration (FDA) has directed manufacturers of popular GLP-1 weight-loss and diabetes medications to add warnings about a rare eye condition that can cause sudden and potentially permanent vision loss.<\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

The updated warning applies to Ozempic, Wegovy, Mounjaro and Zepbound. It concerns nonarteritic anterior ischemic optic neuropathy (NAION)<\/a>, a condition in which reduced blood supply deprives the optic nerve of oxygen, potentially damaging it.<\/p>\n\n\n\n

The FDA said its review of safety reports and scientific studies identified an increased risk of rare NAION events among people taking GLP-1 medications. However, the regulator acknowledged that the exact reason for the possible increased risk remains unknown.<\/p>\n\n\n\n

What Is NAION And How Can It Affect Vision?<\/strong><\/p>\n\n\n\n

NAION is a disorder affecting the optic nerve, which carries visual information from the eye to the brain. It occurs when blood flow to the optic nerve is reduced or blocked.<\/p>\n\n\n\n

The condition can cause sudden, painless loss of vision in one eye. In some cases, the damage can be permanent.<\/p>\n\n\n\n

According to the American Academy of Ophthalmology, NAION is the most common cause of acute optic nerve injury among people over the age of 50.<\/p>\n\n\n\n

There is currently no known treatment that can reverse vision loss caused by the condition. This makes early medical evaluation particularly important when someone experiences sudden changes in vision.<\/p>\n\n\n\n

FDA Review Identifies Possible Increased Risk<\/strong><\/p>\n\n\n\n

The FDA examined reports of NAION among GLP-1 medication users, alongside findings from other scientific studies. Its review concluded that people taking these medicines may face an increased risk of developing the rare eye condition.<\/p>\n\n\n\n

However, establishing a direct relationship is complicated because many patients taking GLP-1 medications for obesity and type 2 diabetes may already have independent risk factors for NAION.<\/p>\n\n\n\n

Research published two years ago involving 17,000 patients found that people taking semaglutide were four times more likely to receive a NAION diagnosis than those not taking the medication.<\/p>\n\n\n\n

One of the study’s authors, Harvard Medical School ophthalmology professor Dr Joseph Rizzo, described the findings as significant but tentative, emphasising the need for further research involving more diverse populations.<\/p>\n\n\n\n

Last year, a safety committee of the European Medicines Agency estimated that NAION could affect up to one in 10,000 people taking semaglutide.<\/p>\n\n\n\n

Drug Manufacturers Question Direct Causation<\/strong><\/p>\n\n\n\n

Novo Nordisk, the manufacturer of Wegovy and Ozempic, said available data do not establish a cause-and-effect relationship between its medicines and NAION.<\/p>\n\n\n\n

The company said patient safety remains a priority and that it continues to monitor the safety of its medications.<\/p>\n\n\n\n

The American Academy of Ophthalmology has also emphasised that any additional risk appears small and that a direct causal relationship has not been established.<\/p>\n\n\n\n

The organisation has advised patients not to discontinue prescribed medication without consulting their doctors. Anyone experiencing sudden, painless vision loss in one eye should seek prompt evaluation from an ophthalmologist.<\/p>\n\n\n\n

Existing GLP-1 Medicines Already Carry Other Warnings<\/strong><\/p>\n\n\n\n

GLP-1 medications are widely prescribed for managing type 2 diabetes and obesity. Some also offer important benefits for people with cardiovascular conditions.<\/p>\n\n\n\n

However, these medicines already carry warnings about potential complications, including pancreatitis and gallbladder disease.<\/p>\n\n\n\n

Common side effects associated with semaglutide include nausea, vomiting and stomach pain. The latest FDA directive adds another safety consideration for patients and healthcare professionals when assessing treatment risks.<\/p>\n\n\n\n

Summary<\/strong><\/p>\n\n\n\n

The FDA has ordered manufacturers of Ozempic, Wegovy, Mounjaro and Zepbound to add warnings about NAION, a rare eye condition that can cause permanent vision loss. Although studies suggest a possible increased risk, a direct causal relationship has not been established. Medical experts advise patients not to stop treatment without consulting their doctors and to seek immediate care for sudden vision loss.<\/p>\n","protected":false},"excerpt":{"rendered":"

The US Food and Drug Administration (FDA) has directed manufacturers of popular GLP-1 weight-loss and diabetes medications to add warnings about a rare eye condition that can cause sudden and potentially permanent vision loss. The updated warning applies to Ozempic, Wegovy, Mounjaro and Zepbound. It concerns nonarteritic anterior ischemic optic neuropathy (NAION), a condition in […]<\/p>\n","protected":false},"author":30,"featured_media":1315678,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[401],"tags":[5672,5673],"class_list":["post-1315670","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-healthcare","tag-glp-1","tag-weight-loss"],"acf":[],"yoast_head":"\nPopular GLP-1 Weight Loss Drugs Can Cause Permanent Blindness - US FDA - Trak.in - Indian Business of Tech, Mobile & Startups<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/trak.in\/stories\/popular-glp-1-weight-loss-drugs-can-cause-permanent-blindness-us-fda\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Popular GLP-1 Weight Loss Drugs Can Cause Permanent Blindness - US FDA - Trak.in - Indian Business of Tech, Mobile & Startups\" \/>\n<meta property=\"og:description\" content=\"The US Food and Drug Administration (FDA) has directed manufacturers of popular GLP-1 weight-loss and diabetes medications to add warnings about a rare eye condition that can cause sudden and potentially permanent vision loss. The updated warning applies to Ozempic, Wegovy, Mounjaro and Zepbound. It concerns nonarteritic anterior ischemic optic neuropathy (NAION), a condition in […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/trak.in\/stories\/popular-glp-1-weight-loss-drugs-can-cause-permanent-blindness-us-fda\/\" \/>\n<meta property=\"og:site_name\" content=\"Trak.in - Indian Business of Tech, Mobile & Startups\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-11T06:34:39+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-11-11T06:34:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/trak.in\/stories\/wp-content\/uploads\/2026\/11\/Screenshot-2025-06-25-at-10.29.14-AM-1024x628.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"628\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Mohul Ghosh\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Mohul Ghosh\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/trak.in\/stories\/popular-glp-1-weight-loss-drugs-can-cause-permanent-blindness-us-fda\/\",\"url\":\"https:\/\/trak.in\/stories\/popular-glp-1-weight-loss-drugs-can-cause-permanent-blindness-us-fda\/\",\"name\":\"Popular GLP-1 Weight Loss Drugs Can Cause Permanent Blindness - US FDA - Trak.in - Indian Business of Tech, Mobile & Startups\",\"isPartOf\":{\"@id\":\"https:\/\/trak.in\/stories\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/trak.in\/stories\/popular-glp-1-weight-loss-drugs-can-cause-permanent-blindness-us-fda\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/trak.in\/stories\/popular-glp-1-weight-loss-drugs-can-cause-permanent-blindness-us-fda\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/trak.in\/stories\/wp-content\/uploads\/2026\/11\/Screenshot-2025-06-25-at-10.29.14-AM.png\",\"datePublished\":\"2026-11-11T06:34:39+00:00\",\"dateModified\":\"2026-11-11T06:34:54+00:00\",\"author\":{\"@id\":\"https:\/\/trak.in\/stories\/#\/schema\/person\/5092a7d2906e3f3c819643435477c2a7\"},\"breadcrumb\":{\"@id\":\"https:\/\/trak.in\/stories\/popular-glp-1-weight-loss-drugs-can-cause-permanent-blindness-us-fda\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/trak.in\/stories\/popular-glp-1-weight-loss-drugs-can-cause-permanent-blindness-us-fda\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/trak.in\/stories\/popular-glp-1-weight-loss-drugs-can-cause-permanent-blindness-us-fda\/#primaryimage\",\"url\":\"https:\/\/trak.in\/stories\/wp-content\/uploads\/2026\/11\/Screenshot-2025-06-25-at-10.29.14-AM.png\",\"contentUrl\":\"https:\/\/trak.in\/stories\/wp-content\/uploads\/2026\/11\/Screenshot-2025-06-25-at-10.29.14-AM.png\",\"width\":2092,\"height\":1284},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/trak.in\/stories\/popular-glp-1-weight-loss-drugs-can-cause-permanent-blindness-us-fda\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/trak.in\/stories\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Popular GLP-1 Weight Loss Drugs Can Cause Permanent Blindness – US FDA\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/trak.in\/stories\/#website\",\"url\":\"https:\/\/trak.in\/stories\/\",\"name\":\"Trak.in - Indian Business of Tech, Mobile & Startups\",\"description\":\"Trak.in is a popular Indian Business, Technology, Mobile & Startup blog featuring trending News, views and analytical take on Technology, Business, Finance, Telecom, Mobile, startups & Social Media Space\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/trak.in\/stories\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/trak.in\/stories\/#\/schema\/person\/5092a7d2906e3f3c819643435477c2a7\",\"name\":\"Mohul Ghosh\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/trak.in\/stories\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/66c129d83dd3f325a3b550eb1aa16891173ddfc4686361424206cd9a01311c89?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/66c129d83dd3f325a3b550eb1aa16891173ddfc4686361424206cd9a01311c89?s=96&d=mm&r=g\",\"caption\":\"Mohul Ghosh\"},\"url\":\"https:\/\/trak.in\/stories\/author\/mohul-ghosh\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Popular GLP-1 Weight Loss Drugs Can Cause Permanent Blindness - US FDA - Trak.in - Indian Business of Tech, Mobile & Startups","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/trak.in\/stories\/popular-glp-1-weight-loss-drugs-can-cause-permanent-blindness-us-fda\/","og_locale":"en_US","og_type":"article","og_title":"Popular GLP-1 Weight Loss Drugs Can Cause Permanent Blindness - US FDA - Trak.in - Indian Business of Tech, Mobile & Startups","og_description":"The US Food and Drug Administration (FDA) has directed manufacturers of popular GLP-1 weight-loss and diabetes medications to add warnings about a rare eye condition that can cause sudden and potentially permanent vision loss. The updated warning applies to Ozempic, Wegovy, Mounjaro and Zepbound. It concerns nonarteritic anterior ischemic optic neuropathy (NAION), a condition in […]","og_url":"https:\/\/trak.in\/stories\/popular-glp-1-weight-loss-drugs-can-cause-permanent-blindness-us-fda\/","og_site_name":"Trak.in - Indian Business of Tech, Mobile & Startups","article_published_time":"2026-11-11T06:34:39+00:00","article_modified_time":"2026-11-11T06:34:54+00:00","og_image":[{"width":1024,"height":628,"url":"https:\/\/trak.in\/stories\/wp-content\/uploads\/2026\/11\/Screenshot-2025-06-25-at-10.29.14-AM-1024x628.png","type":"image\/png"}],"author":"Mohul Ghosh","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Mohul Ghosh","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/trak.in\/stories\/popular-glp-1-weight-loss-drugs-can-cause-permanent-blindness-us-fda\/","url":"https:\/\/trak.in\/stories\/popular-glp-1-weight-loss-drugs-can-cause-permanent-blindness-us-fda\/","name":"Popular GLP-1 Weight Loss Drugs Can Cause Permanent Blindness - US FDA - Trak.in - Indian Business of Tech, Mobile & Startups","isPartOf":{"@id":"https:\/\/trak.in\/stories\/#website"},"primaryImageOfPage":{"@id":"https:\/\/trak.in\/stories\/popular-glp-1-weight-loss-drugs-can-cause-permanent-blindness-us-fda\/#primaryimage"},"image":{"@id":"https:\/\/trak.in\/stories\/popular-glp-1-weight-loss-drugs-can-cause-permanent-blindness-us-fda\/#primaryimage"},"thumbnailUrl":"https:\/\/trak.in\/stories\/wp-content\/uploads\/2026\/11\/Screenshot-2025-06-25-at-10.29.14-AM.png","datePublished":"2026-11-11T06:34:39+00:00","dateModified":"2026-11-11T06:34:54+00:00","author":{"@id":"https:\/\/trak.in\/stories\/#\/schema\/person\/5092a7d2906e3f3c819643435477c2a7"},"breadcrumb":{"@id":"https:\/\/trak.in\/stories\/popular-glp-1-weight-loss-drugs-can-cause-permanent-blindness-us-fda\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/trak.in\/stories\/popular-glp-1-weight-loss-drugs-can-cause-permanent-blindness-us-fda\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/trak.in\/stories\/popular-glp-1-weight-loss-drugs-can-cause-permanent-blindness-us-fda\/#primaryimage","url":"https:\/\/trak.in\/stories\/wp-content\/uploads\/2026\/11\/Screenshot-2025-06-25-at-10.29.14-AM.png","contentUrl":"https:\/\/trak.in\/stories\/wp-content\/uploads\/2026\/11\/Screenshot-2025-06-25-at-10.29.14-AM.png","width":2092,"height":1284},{"@type":"BreadcrumbList","@id":"https:\/\/trak.in\/stories\/popular-glp-1-weight-loss-drugs-can-cause-permanent-blindness-us-fda\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/trak.in\/stories\/"},{"@type":"ListItem","position":2,"name":"Popular GLP-1 Weight Loss Drugs Can Cause Permanent Blindness – US FDA"}]},{"@type":"WebSite","@id":"https:\/\/trak.in\/stories\/#website","url":"https:\/\/trak.in\/stories\/","name":"Trak.in - Indian Business of Tech, Mobile & Startups","description":"Trak.in is a popular Indian Business, Technology, Mobile & Startup blog featuring trending News, views and analytical take on Technology, Business, Finance, Telecom, Mobile, startups & Social Media Space","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/trak.in\/stories\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/trak.in\/stories\/#\/schema\/person\/5092a7d2906e3f3c819643435477c2a7","name":"Mohul Ghosh","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/trak.in\/stories\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/66c129d83dd3f325a3b550eb1aa16891173ddfc4686361424206cd9a01311c89?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/66c129d83dd3f325a3b550eb1aa16891173ddfc4686361424206cd9a01311c89?s=96&d=mm&r=g","caption":"Mohul Ghosh"},"url":"https:\/\/trak.in\/stories\/author\/mohul-ghosh\/"}]}},"jetpack_featured_media_url":"https:\/\/trak.in\/stories\/wp-content\/uploads\/2026\/11\/Screenshot-2025-06-25-at-10.29.14-AM.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/trak.in\/stories\/wp-json\/wp\/v2\/posts\/1315670","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/trak.in\/stories\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/trak.in\/stories\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/trak.in\/stories\/wp-json\/wp\/v2\/users\/30"}],"replies":[{"embeddable":true,"href":"https:\/\/trak.in\/stories\/wp-json\/wp\/v2\/comments?post=1315670"}],"version-history":[{"count":1,"href":"https:\/\/trak.in\/stories\/wp-json\/wp\/v2\/posts\/1315670\/revisions"}],"predecessor-version":[{"id":1315679,"href":"https:\/\/trak.in\/stories\/wp-json\/wp\/v2\/posts\/1315670\/revisions\/1315679"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/trak.in\/stories\/wp-json\/wp\/v2\/media\/1315678"}],"wp:attachment":[{"href":"https:\/\/trak.in\/stories\/wp-json\/wp\/v2\/media?parent=1315670"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/trak.in\/stories\/wp-json\/wp\/v2\/categories?post=1315670"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/trak.in\/stories\/wp-json\/wp\/v2\/tags?post=1315670"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}